$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

$lgnd Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000088616315000085 Filed on August 05, 2015

Income Statement

Concept	2015 Q2	2014 Q2
Revenue	$18.42M	$10.61M
YoY Change	73.62%	10.73%
Cost Of Revenue	$2.600M	$1.186M
YoY Change	119.22%	-2.31%
Gross Profit	$15.82M	$9.422M
YoY Change	67.88%	12.62%
Gross Profit Margin	85.88%	88.82%
Selling, General & Admin	$7.230M	$5.240M
YoY Change	37.98%	21.58%
% of Gross Profit	45.71%	55.61%
Research & Development	$3.416M	$2.689M
YoY Change	27.04%	32.99%
% of Gross Profit	21.6%	28.54%
Depreciation & Amortization	$635.0K	$669.0K
YoY Change	-5.08%	0.0%
% of Gross Profit	4.01%	7.1%
Operating Expenses	$3.416M	$2.689M
YoY Change	27.04%	32.99%
Operating Profit	$4.365M	$1.358M
YoY Change	221.43%	-10.3%
Interest Expense	$2.969M	$181.0K
YoY Change	1540.33%	-60.04%
% of Operating Profit	68.02%	13.33%
Other Income/Expense, Net	$17.93M	-$117.0K
YoY Change	-15422.22%	-105.11%
Pretax Income	$22.29M	$1.241M
YoY Change	1696.29%	-67.38%
Income Tax	$265.0K	-$47.00K
% Of Pretax Income	1.19%	-3.79%
Net Earnings	$23.56M	$1.592M
YoY Change	1380.15%	-73.86%
Net Earnings / Revenue	127.94%	15.01%
Basic Earnings Per Share	$1.19	$0.08
Diluted Earnings Per Share	$1.11	$0.07
COMMON SHARES
Basic Shares Outstanding	19.73M shares	20.74M shares
Diluted Shares Outstanding	21.28M shares	21.78M shares

Balance Sheet

Concept	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$181.6M	$22.00M
YoY Change	725.45%	272.88%
Cash & Equivalents	$108.2M	$14.54M
Short-Term Investments	$73.40M	$7.500M
Other Short-Term Assets	$1.801M	$1.123M
YoY Change	60.37%	-7.27%
Inventory	$802.0K	$817.0K
Prepaid Expenses	$1.206M	$745.0K
Receivables	$5.500M	$3.100M
Other Receivables	$7.000M	$800.0K
Total Short-Term Assets	$196.7M	$28.59M
YoY Change	588.21%	96.19%
LONG-TERM ASSETS
Property, Plant & Equipment	$405.0K	$619.0K
YoY Change	-34.57%	-23.01%
Goodwill	$12.24M	$12.24M
YoY Change	0.0%	0.0%
Intangibles	$49.54M	$51.91M
YoY Change	-4.58%	-4.3%
Long-Term Investments	$34.00M
YoY Change
Other Assets	$301.0K	$253.0K
YoY Change	18.97%	-35.79%
Total Long-Term Assets	$108.0M	$71.26M
YoY Change	51.61%	-16.16%
TOTAL ASSETS
Total Short-Term Assets	$196.7M	$28.59M
Total Long-Term Assets	$108.0M	$71.26M
Total Assets	$304.8M	$99.85M
YoY Change	205.23%	0.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.708M	$5.059M
YoY Change	-46.47%	6.39%
Accrued Expenses	$5.629M	$3.241M
YoY Change	73.68%	-19.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.600M	$5.400M
YoY Change	-70.37%	-67.27%
Total Short-Term Liabilities	$17.95M	$18.62M
YoY Change	-3.61%	-42.83%
LONG-TERM LIABILITIES
Long-Term Debt	$200.8M	$1.600M
YoY Change	12450.0%	-74.6%
Other Long-Term Liabilities	$734.0K	$728.0K
YoY Change	0.82%	8.17%
Total Long-Term Liabilities	$734.0K	$728.0K
YoY Change	0.82%	8.17%
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.95M	$18.62M
Total Long-Term Liabilities	$734.0K	$728.0K
Total Liabilities	$235.7M	$36.76M
YoY Change	541.19%	-39.04%
SHAREHOLDERS EQUITY
Retained Earnings	-$635.0M	-$667.7M
YoY Change	-4.89%	-1.11%
Common Stock	$20.00K	$21.00K
YoY Change	-4.76%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$69.05M	$64.17M
YoY Change
Total Liabilities & Shareholders Equity	$304.8M	$99.85M
YoY Change	205.23%	0.28%

Cashflow Statement

Concept	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	$23.56M	$1.592M
YoY Change	1380.15%	-73.86%
Depreciation, Depletion And Amortization	$635.0K	$669.0K
YoY Change	-5.08%	0.0%
Cash From Operating Activities	$10.00M	$4.000M
YoY Change	150.0%	-42.03%
INVESTING ACTIVITIES
Capital Expenditures	-$4.100M	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$68.20M	$600.0K
YoY Change	-11466.67%
Cash From Investing Activities	-$72.20M	$600.0K
YoY Change	-12133.33%	-116.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.600M	-3.100M
YoY Change	-248.39%	34.78%
NET CHANGE
Cash From Operating Activities	10.00M	4.000M
Cash From Investing Activities	-72.20M	600.0K
Cash From Financing Activities	4.600M	-3.100M
Net Change In Cash	-57.60M	1.500M
YoY Change	-3940.0%	66.67%
FREE CASH FLOW
Cash From Operating Activities	$10.00M	$4.000M
Capital Expenditures	-$4.100M	$0.00
Free Cash Flow	$14.10M	$4.000M
YoY Change	252.5%	-62.26%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Type DocumentType	10-Q
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-06-30
	dei	Entity Central Index Key EntityCentralIndexKey	0000886163
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19854830	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	LIGAND PHARMACEUTICALS INC
CY2014Q4	lgnd	Capitalized Initial Public Offering Expenses CapitalizedInitialPublicOfferingExpenses	2268000	USD
CY2015Q2	lgnd	Capitalized Initial Public Offering Expenses CapitalizedInitialPublicOfferingExpenses	0	USD
CY2014Q4	lgnd	Co Promote Termination Payments Receivable Current CoPromoteTerminationPaymentsReceivableCurrent	322000	USD
CY2015Q2	lgnd	Co Promote Termination Payments Receivable Current CoPromoteTerminationPaymentsReceivableCurrent	0	USD
CY2014Q2	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	1891000	USD
	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	4284000	USD
CY2015Q2	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	1131000	USD
	lgnd	Collaborative Research And Development And Other Revenues CollaborativeResearchAndDevelopmentAndOtherRevenues	1717000	USD
CY2014Q4	lgnd	Commercial License Rights CommercialLicenseRights	4568000	USD
CY2015Q2	lgnd	Commercial License Rights CommercialLicenseRights	8598000	USD
CY2014Q4	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	6796000	USD
CY2015Q2	lgnd	Current Portion Of Liability For Contingent Value Rights CurrentPortionOfLiabilityForContingentValueRights	7674000	USD
CY2014Q4	lgnd	Deposits Liabilities Noncurrent DepositsLiabilitiesNoncurrent	411000	USD
CY2015Q2	lgnd	Deposits Liabilities Noncurrent DepositsLiabilitiesNoncurrent	396000	USD
CY2014Q3	lgnd	Exercise Priceof Convertible Bond Hedge ExercisePriceofConvertibleBondHedge	75.05
	lgnd	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Fair Value Adjustment FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetFairValueAdjustment	68000	USD
	lgnd	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Fair Value Adjustment Co Promotion Termination FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentCoPromotionTermination	68000	USD
	lgnd	Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Liability Fair Value Adjustment Contingent Liabilities FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities	2169000	USD
	lgnd	Lease Expiration Year Maximum LeaseExpirationYearMaximum	2019
	lgnd	Lease Expiration Year Minimum LeaseExpirationYearMinimum	2015
CY2014Q4	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	8353000	USD
CY2015Q2	lgnd	Liability For Contingent Value Rights LiabilityForContingentValueRights	11089000	USD
CY2014Q3	lgnd	Line Of Credit Facility Additional Payment On Borrowings Percentage LineOfCreditFacilityAdditionalPaymentOnBorrowingsPercentage	0.06
CY2014Q4	lgnd	Long Term Portion Of Lease Exit Obligations LongTermPortionOfLeaseExitObligations	934000	USD
CY2015Q2	lgnd	Long Term Portion Of Lease Exit Obligations LongTermPortionOfLeaseExitObligations	228000	USD
	lgnd	Maturity Period Of Highly Liquid Securities Maximum MaturityPeriodOfHighlyLiquidSecuritiesMaximum	P3M
	lgnd	Maximum Period For Accounts Receivable Outstanding To Be Considered As Past Due MaximumPeriodForAccountsReceivableOutstandingToBeConsideredAsPastDue	P90D
	lgnd	Minimum Period For Accounts Receivable Outstanding To Be Considered As Past Due MinimumPeriodForAccountsReceivableOutstandingToBeConsideredAsPastDue	P30D
	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-3261000	USD
	lgnd	Non Cash Change In Estimated Fair Value Of Contingent Value Rights NonCashChangeInEstimatedFairValueOfContingentValueRights	-7277000	USD
	lgnd	Non Restricted Equity And Debt Securities With Maturity Period NonRestrictedEquityAndDebtSecuritiesWithMaturityPeriod	P3M
	lgnd	Noncash Upfront Fee NoncashUpfrontFee	1211000	USD
	lgnd	Noncash Upfront Fee NoncashUpfrontFee	0	USD
CY2015Q2	lgnd	Number Of Drugs Included In Product Line NumberOfDrugsIncludedInProductLine	4	drug
CY2014Q2	lgnd	Operating Lease Adjustment For Accretion And Changes In Lease Assumptions OperatingLeaseAdjustmentForAccretionAndChangesInLeaseAssumptions	100000	USD
	lgnd	Operating Lease Adjustment For Accretion And Changes In Lease Assumptions OperatingLeaseAdjustmentForAccretionAndChangesInLeaseAssumptions	200000	USD
CY2015Q2	lgnd	Operating Lease Adjustment For Accretion And Changes In Lease Assumptions OperatingLeaseAdjustmentForAccretionAndChangesInLeaseAssumptions	200000	USD
	lgnd	Operating Lease Adjustment For Accretion And Changes In Lease Assumptions OperatingLeaseAdjustmentForAccretionAndChangesInLeaseAssumptions	400000	USD
CY2015Q2	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Five OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearFive	0	USD
CY2015Q2	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearFour	278000	USD
CY2015Q2	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearThree	297000	USD
CY2015Q2	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Duein Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsDueinRollingYearTwo	718000	USD
	lgnd	Purchasefor Commercial License Rights PurchaseforCommercialLicenseRights	4030000	USD
CY2015Q2	lgnd	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentalsNextRollingTwelveMonths	2824000	USD
CY2015Q2	lgnd	Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate Maximum OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRateMaximum	0.035
CY2015Q2	lgnd	Operating Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate Minimum OperatingLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRateMinimum	0.03
CY2014Q4	lgnd	Other Other Liabilities Noncurrent OtherOtherLiabilitiesNoncurrent	32000	USD
CY2015Q2	lgnd	Other Other Liabilities Noncurrent OtherOtherLiabilitiesNoncurrent	32000	USD
	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	1668000	USD
	lgnd	Payments To Contingent Value Right Holders PaymentsToContingentValueRightHolders	3663000	USD
	lgnd	Period Allowed For Return Of Products Maximum PeriodAllowedForReturnOfProductsMaximum	P90D
	lgnd	Period Allowed For Return Of Products Minimum PeriodAllowedForReturnOfProductsMinimum	P30D
	lgnd	Product Shelf Life ProductShelfLife	P5Y
	lgnd	Purchasefor Commercial License Rights PurchaseforCommercialLicenseRights	0	USD
	lgnd	Sales Returns Restocking Fee Percent SalesReturnsRestockingFeePercent	0.2
CY2014Q2	lgnd	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueForfeitureRate	0.086
CY2015Q2	lgnd	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueForfeitureRate	0.085
	lgnd	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueForfeitureRate	0.085
CY2014Q4	lgnd	Short Term Portion Of Lease Exit Obligations ShortTermPortionOfLeaseExitObligations	2356000	USD
CY2015Q2	lgnd	Short Term Portion Of Lease Exit Obligations ShortTermPortionOfLeaseExitObligations	1638000	USD
CY2014Q4	lgnd	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	809000	USD
CY2015Q2	lgnd	Unamortized Debt Issuance Expense Current UnamortizedDebtIssuanceExpenseCurrent	834000	USD
	lgnd	Variable Interest Entity Qualitativeor Quantitative Information Loss Percentage Recorded VariableInterestEntityQualitativeorQuantitativeInformationLossPercentageRecorded	1
CY2014Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	685000	USD
CY2015Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	595000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7698000	USD
CY2015Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2708000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	34000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4866000	USD
CY2015Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5629000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	459000	USD
CY2015Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	545000	USD
CY2014Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	705000	USD
CY2015Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	634000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2643000	USD
CY2015Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2682000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4953000	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	11265000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	680660000	USD
CY2015Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	692765000	USD
CY2014Q3	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	11600000	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	3027000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	5093000	USD
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	3760000	USD
	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	6675000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2015Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	5058000	USD
CY2014Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
CY2015Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	600000	USD
CY2015Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	73971000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	4954000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	400000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3500000	shares
CY2014Q4	us-gaap	Assets Assets	258029000	USD
CY2015Q2	us-gaap	Assets Assets	304762000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	186419000	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	196725000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	8394000	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11277000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2015Q2	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	11000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	3440000	USD
CY2015Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	62705000	USD
CY2014Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-1312000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-3260000	USD
CY2015Q2	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-7274000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	-7277000	USD
CY2014Q2	us-gaap	Business Exit Costs1 BusinessExitCosts1	136000	USD
	us-gaap	Business Exit Costs1 BusinessExitCosts1	340000	USD
CY2015Q2	us-gaap	Business Exit Costs1 BusinessExitCosts1	218000	USD
	us-gaap	Business Exit Costs1 BusinessExitCosts1	441000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11639000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14536000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160203000	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108238000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2897000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-51965000	USD
	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0	USD
	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	247000	USD
CY2014Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	125.08
CY2014Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3264643	shares
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	33333333	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19575150	shares
CY2015Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19837109	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19575150	shares
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19837109	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	20000	USD
	us-gaap	Net Income Loss NetIncomeLoss	3688000	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4309000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	5815000	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	25494000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	30629000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	195908000	USD
CY2015Q2	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	200567000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1186000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3637000	USD
CY2015Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2600000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3673000	USD
CY2014Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0	USD
CY2015Q2	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	28190000	USD
	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	28190000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	327000	USD
CY2015Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	306000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1063000	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	300000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2085000	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2083000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	2792000	USD
CY2015Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	3059000	USD
CY2014Q2	us-gaap	Depreciation Depreciation	100000	USD
	us-gaap	Depreciation Depreciation	100000	USD
CY2015Q2	us-gaap	Depreciation Depreciation	100000	USD
	us-gaap	Depreciation Depreciation	100000	USD
CY2014Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	669000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1337000	USD
CY2015Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	635000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1296000	USD
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.18
CY2015Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.19
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.17
CY2015Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.16
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1708000	USD
CY2015Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1399000	USD
CY2014Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2015Q2	us-gaap	Equity Method Investments EquityMethodInvestments	33996000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements	390000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3	5547000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	322000	USD
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue	5547000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases	3296000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	390000	USD
CY2014Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11819000	USD
CY2015Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10370000	USD
	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P20Y
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	2400000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2400000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2400000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2400000	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2400000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	16000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5239000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10310000	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7225000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13219000	USD
CY2014Q4	us-gaap	Goodwill Goodwill	12238000	USD
CY2015Q2	us-gaap	Goodwill Goodwill	12238000	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	1241000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	3390000	USD
CY2015Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	22292000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	22217000	USD
CY2014Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2015Q2	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-870000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-870000	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-47000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	USD
CY2015Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	265000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	279000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	3000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	13000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3743000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3107000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	911000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-7102000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-6000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-268000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-24000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-110000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	169000	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	16000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-575000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	533000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	231000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	598000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	136000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-661000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	23564000	USD
	us-gaap	Net Income Loss NetIncomeLoss	24318000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	462000	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	0	USD
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	463232	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	231617	shares
CY2014Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1012706	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1063200	shares
CY2015Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1044926	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1001147	shares
CY2014Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	50723000	USD
CY2015Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	49535000	USD
CY2014Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	62961000	USD
CY2015Q2	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	61773000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	181000	USD
	us-gaap	Interest Expense InterestExpense	429000	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	2969000	USD
	us-gaap	Interest Expense InterestExpense	5945000	USD
	us-gaap	Interest Paid InterestPaid	212000	USD
	us-gaap	Interest Paid InterestPaid	903000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	925000	USD
CY2015Q2	us-gaap	Interest Payable Current InterestPayableCurrent	1960000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	269000	USD
CY2015Q2	us-gaap	Inventory Net InventoryNet	802000	USD
CY2014Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2015Q2	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
CY2015Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	100000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	200000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	233621000	USD
CY2015Q2	us-gaap	Liabilities Liabilities	235709000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	258029000	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	304762000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	22779000	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	17949000	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	-1910000	USD
CY2015Q2	us-gaap	Minority Interest MinorityInterest	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3299000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5430000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-389000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75020000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6585000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17625000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	1592000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-125000	USD
	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-1000	USD
CY2014Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-304000	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-304000	USD
CY2015Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1537000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-2380000	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-117000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3068000	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17927000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14502000	USD
CY2014Q4	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	0	USD
CY2015Q2	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	5547000	USD
CY2014Q4	us-gaap	Notes Payable NotesPayable	196242000	USD
CY2015Q2	us-gaap	Notes Payable NotesPayable	200567000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2015Q2	us-gaap	Number Of Stores NumberOfStores	3	storage_location
CY2014Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	9250000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	20108000	USD
CY2015Q2	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	14053000	USD
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	25305000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1358000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	6458000	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	4365000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	7715000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6250000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals	4117000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four OperatingLeasesFutureMinimumPaymentsDueInRollingYearFour	747000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearThree	754000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo	1199000	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths	3550000	USD
CY2014Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1800000	USD
CY2015Q2	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	900000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1900000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1069000	USD
CY2015Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1091000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1842000	USD
CY2015Q2	us-gaap	Other Assets Current OtherAssetsCurrent	1801000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	207000	USD
CY2015Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	301000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5127000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3095000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	3230000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	7844000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	774000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	968000	USD
CY2015Q2	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	1300000	USD
	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	1533000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Payments To Acquire Equity Method Investments PaymentsToAcquireEquityMethodInvestments	9000000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	0	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	770000	USD
CY2015Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	734000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1376000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	621000	USD
CY2015Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	850000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	404000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	1000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	60432000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	835000	USD
CY2015Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1206000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	1155000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	2378000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3648000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5430000	USD
CY2014Q2	us-gaap	Profit Loss ProfitLoss	1288000	USD
	us-gaap	Profit Loss ProfitLoss	3384000	USD
CY2015Q2	us-gaap	Profit Loss ProfitLoss	22027000	USD
	us-gaap	Profit Loss ProfitLoss	21938000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3129000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3087000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	486000	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	405000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	968000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	502000	USD
CY2014Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	12634000	USD
CY2015Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	5532000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6947000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2689000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5821000	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4010000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7972000	USD
CY2014Q4	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	1261000	USD
CY2015Q2	us-gaap	Restricted Cash And Investments Current RestrictedCashAndInvestmentsCurrent	600000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-659315000	USD
CY2015Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-634997000	USD
CY2014Q2	us-gaap	Revenues Revenues	10608000	USD
	us-gaap	Revenues Revenues	26566000	USD
CY2015Q2	us-gaap	Revenues Revenues	18418000	USD
	us-gaap	Revenues Revenues	33020000	USD
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	5241000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	13091000	USD
CY2015Q2	us-gaap	Royalty Revenue RoyaltyRevenue	6606000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	16893000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3476000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	9191000	USD
CY2015Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10681000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	14410000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5093000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6675000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.67
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.69
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.58
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.58
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.019
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.019
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.017
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.018
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1139894	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	23.62
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	78685	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	262747	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	51558000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	120588000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1800697	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1772410	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.78
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	32.86
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	120588000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1772410	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	32.86
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	25.58
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	45.75
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	58.84
CY2014Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y4M24D
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M26D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y6M26D
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	88090000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M10D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M27D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y11M27D
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	7844000	USD
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	7133000	USD
CY2015Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	2964000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	3095000	USD
CY2015Q2	us-gaap	Short Term Investments ShortTermInvestments	73371000	USD
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	212349	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	26318000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	69053000	USD
CY2014Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	3388000	USD
CY2014Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21780034	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21776125	shares
CY2015Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21276404	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20953134	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20738299	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20668110	shares
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19725410	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19668183	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20738299	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20668110	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19725410	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19668183	shares
CY2014Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	29029	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	44815	shares
CY2015Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	42836	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	52187	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash equivalents, investments and accounts receivable.</font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company invests its excess cash principally in U.S. government debt securities, investment-grade corporate debt securities and certificates of deposit. The Company has established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. The Company did not experience any significant losses on its cash equivalents, short-term investments or restricted investments for either of the periods ending </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable were </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">88%</font><font style="font-family:inherit;font-size:10pt;"> was due from </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> customer at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Accounts receivable were </font><font style="font-family:inherit;font-size:10pt;">$12.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">64%</font><font style="font-family:inherit;font-size:10pt;"> was due from </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> customers at </font><font style="font-family:inherit;font-size:10pt;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;text-align:left;text-indent:60px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company currently obtains Captisol material from multiple sites from a single supplier, Hovione.  If Hovione were not able to supply the requested amounts of Captisol and the Company's existing inventory was depleted, the Company would be unable to continue to derive revenues from the sale of Captisol until it obtained an alternative source, which might take considerable time. The Company maintains inventory of Captisol, which has a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> year shelf life, at </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> geographically spread storage locations in the United States and Europe.  If a disaster were to strike any of these locations, it could lead to supply interruptions for some customers. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, contingent assets and liabilities, definite and indefinite lived intangible assets, goodwill, co-promote termination payments receivable and co-promote termination liabilities, uncertain tax positions, deferred revenue, lease exit liability and income tax net operating loss carryforwards during the reporting period. The Company’s critical accounting policies are those that are both most important to the Company’s financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed consolidated financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0000886163-15-000085-index-headers.html	Edgar Link	pending
0000886163-15-000085-index.html	Edgar Link	pending
0000886163-15-000085.txt	Edgar Link	pending
0000886163-15-000085-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lgnd-20150630.xml	Edgar Link	completed
lgnd-20150630.xsd	Edgar Link	pending
lgnd-20150630_cal.xml	Edgar Link	unprocessable
lgnd-20150630_def.xml	Edgar Link	unprocessable
lgnd-20150630_lab.xml	Edgar Link	unprocessable
lgnd-20150630_pre.xml	Edgar Link	unprocessable
lgnd-6301510q.htm	Edgar Link	pending
lgndvikingloanandsecuritya.htm	Edgar Link	pending
lgndvikingmasterlicenseagr.htm	Edgar Link	pending
lgnd_63015exhibit311.htm	Edgar Link	pending
lgnd_63015exhibit312.htm	Edgar Link	pending
lgnd_63015exhibit321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd

2015 Q2 Form 10-Q Financial Statement

#000088616315000085 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND LIGAND PHARMACEUTICALS INC Stock $lgnd

2015 Q2 Form 10-Q Financial Statement

#000088616315000085 Filed on August 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LGND
LIGAND PHARMACEUTICALS INC Stock $lgnd